Download PDF
Pharmacopsychiatry 2022; 55(06): 297-303
DOI: 10.1055/a-1872-0844
Original Paper

Identification of Endocannabinoid Predictors of Treatment Outcomes in Major Depressive Disorder: A Secondary Analysis of the First Canadian Biomarker Integration Network in Depression (CAN-BIND 1) Study

Helena K. Kim
1   Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
,
Gwyneth Zai
1   Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
2   Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada
3   Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Canada
,
Daniel J. Müller
1   Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
2   Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada
,
Muhammad I. Husain
1   Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
2   Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada
,
Raymond W. Lam
4   Department of Psychiatry, University of British Columbia, Vancouver, Canada
,
Benicio N. Frey
5   Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Canada
6   Mood Disorders Program and Women’s Health Concerns Clinic, St. Joseph’s Healthcare, Hamilton, Canada
,
Claudio N. Soares
7   Department of Psychiatry, Queen’s university School of Medicine, Kingston, Canada
,
Sagar V. Parikh
8   Department of Psychiatry, University of Michigan, Ann Arbor, United States of America
,
Roumen Milev
7   Department of Psychiatry, Queen’s university School of Medicine, Kingston, Canada
9   Department of Psychiatry, Providence care, Kingston, Canada
,
Jane A. Foster
5   Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Canada
,
Gustavo Turecki
10   Douglas Institute, Department of Psychiatry, McGill University, Montreal, Canada
,
Faranak Farzan
11   eBrain Lab, School of Mechatronic Systems Engineering, Simon Fraser University, Surrey, Canada
,
Benoit H. Mulsant
1   Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
2   Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada
3   Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Canada
,
Sidney H. Kennedy
1   Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
3   Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Canada
,
Shreejoy J. Tripathy
1   Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
2   Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada
3   Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Canada
12   Krembil Center for Neuroinformatics, Centre for Addiction and Mental Health, Toronto, Canada
13   Department of Physiology, University of Toronto, Toronto, Canada
,
Stefan Kloiber
1   Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada
2   Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Canada
3   Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Canada
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Introduction An increasing number of studies are examining the link between the endocannabinoidome and major depressive disorder (MDD). We conducted an exploratory analysis of this system to identify potential markers of treatment outcomes.

Methods The dataset of the Canadian Biomarker Integration Network in Depression-1 study, consisting of 180 patients with MDD treated for eight weeks with escitalopram followed by eight weeks with escitalopram alone or augmented with aripiprazole was analyzed. Association between response Montgomery-Asberg Depression Rating Scale (MADRS; score reduction≥50%) or remission (MADRS score≤10) at weeks 8 and 16 and single nucleotide polymorphisms (SNPs), methylation, and mRNA levels of 33 endocannabinoid markers were examined. A standard genome-wide association studies protocol was used for identifying SNPs, and logistic regression was used to assess methylation and mRNA levels.

Results Lower methylation of CpG islands of the diacylglycerol lipase alpha gene (DAGLA) was associated with non-remission at week 16 (DAGLA; OR=0.337, p<0.003, q=0.050). Methylation of DAGLA was correlated with improvement in Clinical Global Impression (p=0.026), Quick Inventory of Depressive Symptomatology (p=0.010), and Snaith-Hamilton Pleasure scales (p=0.028). We did not find any association between SNPs or mRNA levels and treatment outcomes.

Discussion Methylation of DAGLA is a promising candidate as a marker of treatment outcomes for MDD and needs to be explored further.

Key words

endocannabinoid - major depressive disorder - methylation - DAGLA - antidepressant

Supplementary Material



Publication History

Received: 26 April 2022
Received: 31 May 2022

Accepted: 27 May 2022

Article published online:
06 July 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Friedrich MJ. Depression is the leading cause of disability around the world. JAMA 2017; 317: 1517
    CrossrefPubMedGoogle Scholar
  • 2 Rush AJ, Trivedi MH, Wisniewski SR. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917
    Google Scholar
  • 3 Trivedi MH, Rush AJ, Wisniewski SR. et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry 2006; 163: 28-40
    CrossrefPubMedGoogle Scholar
  • 4 Kennedy SH, Lam RW, McIntyre RS. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry 2016; 61: 540-560
    CrossrefPubMedGoogle Scholar
  • 5 Joel I, Begley AE, Mulsant BH. et al. Dynamic prediction of treatment response in late-life depression. Am J Geriatr Psychiatry 2014; 22: 167-176
    CrossrefPubMedGoogle Scholar
  • 6 Karyotaki E, Smit Y, Holdt Henningsen K. et al. Combining pharmacotherapy and psychotherapy or monotherapy for major depression? A meta-analysis on the long-term effects. J Affect Disord 2016; 194: 144-152
    CrossrefPubMedGoogle Scholar
  • 7 Fitzgibbon KP, Plett D, Chan BCF. et al. Cost-utility analysis of electroconvulsive therapy and repetitive transcranial magnetic stimulation for treatment-resistant depression in Ontario. Can J Psychiatry 2020; 65: 164-173
    PubMedGoogle Scholar
  • 8 Mackie K. Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol 2005; 168: 299-325
    CrossrefPubMedGoogle Scholar
  • 9 Morena M, Patel S, Bains JS. et al. Neurobiological interactions between stress and the endocannabinoid system. Neuropsychopharmacology 2016; 41: 80-102
    Google Scholar
  • 10 Ibarra-Lecue I, Pilar-Cuéllar F, Muguruza C. et al. The endocannabinoid system in mental disorders: Evidence from human brain studies. Biochem Pharmacol 2018; 157: 97-107
    CrossrefPubMedGoogle Scholar
  • 11 Navarrete F, Garcia-Gutierrez MS, Jurado-Barba R. et al. Endocannabinoid system components as potential biomarkers in psychiatry. Front Psychiatry 2020; 11: 315
    CrossrefPubMedGoogle Scholar
  • 12 Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol 2020; 16: 9-29
    CrossrefPubMedGoogle Scholar
  • 13 Howlett AC, Barth F, Bonner TI. et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews 2002; 54: 161-202
    CrossrefPubMedGoogle Scholar
  • 14 Di Marzo V, Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: ‘Killing two birds with one stone’. Prostaglandins Leukot Essent Fatty Acids 1995; 53: 1-11
    CrossrefPubMedGoogle Scholar
  • 15 Imperatore R, Morello G, Luongo L. et al. Genetic deletion of monoacylglycerol lipase leads to impaired cannabinoid receptor CB(1)R signaling and anxiety-like behavior. J Neurochem 2015; 135: 799-813
    CrossrefPubMedGoogle Scholar
  • 16 Simon GM, Cravatt BF. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of glycerophospho-N-acyl ethanolamine precursors in mouse brain. J Biol Chem 2008; 283: 9341-9349
    CrossrefPubMedGoogle Scholar
  • 17 Moreira FA, Crippa JA. The psychiatric side-effects of rimonabant. Braz J Psychiatry 2009; 31: 145-153
    CrossrefPubMedGoogle Scholar
  • 18 Martin M, Ledent C, Parmentier M. et al. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 2002; 159: 379-387
    CrossrefPubMedGoogle Scholar
  • 19 Hill MN, Miller GE, Ho WS. et al. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry 2008; 41: 48-53
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Hill MN, Ho WS, Hillard CJ. et al. Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents. J Neural Transm (Vienna) 2008; 115: 1673-1679
    CrossrefPubMedGoogle Scholar
  • 21 Smaga I, Bystrowska B, Gawlinski D. et al. Antidepressants and changes in concentration of endocannabinoids and N-acylethanolamines in rat brain structures. Neurotox Res 2014; 26: 190-206
    CrossrefPubMedGoogle Scholar
  • 22 Kranaster L, Hoyer C, Aksay SS. et al. Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: A preliminary prospective study. Eur Arch Psychiatry Clin Neurosci 2017; 267: 781-786
    CrossrefPubMedGoogle Scholar
  • 23 Kennedy SH, Lam RW, Rotzinger S. et al. Symptomatic and functional outcomes and early prediction of response to escitalopram monotherapy and sequential adjunctive aripiprazole therapy in patients with major depressive disorder: A CAN-BIND-1 Report. J Clin Psychiatry. 2019 80. 18m12202
    PubMedGoogle Scholar
  • 24 Lam RW, Milev R, Rotzinger S. et al. Discovering biomarkers for antidepressant response: Protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry 2016; 16: 105
    CrossrefPubMedGoogle Scholar
  • 25 Yrondi A, Fiori LM, Frey BN. et al. Association between side effects and blood microRNA expression levels and their targeted pathways in patients with major depressive disorder treated by a selective serotonin reuptake inhibitor, Escitalopram: A CAN-BIND-1 Report. Int J Neuropsychopharmacol 2020; 23: 88-95
    CrossrefPubMedGoogle Scholar
  • 26 Marshe VS, Maciukiewicz M, Hauschild AC. et al. Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. Transl Psychiatry 2021; 11: 127
    CrossrefPubMedGoogle Scholar
  • 27 Ju C, Fiori LM, Belzeaux R. et al. Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. Transl Psychiatry 2019; 9: 254
    CrossrefPubMedGoogle Scholar
  • 28 Association AP. Diagnostic and Statistical Manual of Mental Disorders 4th Ed. Text Revision. ed. American Psychiatric Association; 2000
    Google Scholar
  • 29 Sheehan DV, Lecrubier Y, Sheehan KH. et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59: 22-33 quiz 4-57
    PubMedGoogle Scholar
  • 30 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389
    Google Scholar
  • 31 Purcell S, Neale B, Todd-Brown K. et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575
    CrossrefPubMedGoogle Scholar
  • 32 Maciukiewicz M, Marshe VS, Tiwari AK. et al. Genome-wide association studies of placebo and duloxetine response in major depressive disorder. Pharmacogenomics J 2018; 18: 406-412
    CrossrefPubMedGoogle Scholar
  • 33 Jeziorska DM, Murray RJS, De Gobbi M. et al. DNA methylation of intragenic CpG islands depends on their transcriptional activity during differentiation and disease. Proc Natl Acad Sci U S A 2017; 114: E7526-E7535
    CrossrefPubMedGoogle Scholar
  • 34 Affinito O, Palumbo D, Fierro A. et al. Nucleotide distance influences co-methylation between nearby CpG sites. Genomics 2020; 112: 144-150
    CrossrefPubMedGoogle Scholar
  • 35 Wang D, Yan L, Hu Q. et al. IMA: An R package for high-throughput analysis of Illumina’s 450K Infinium methylation data. Bioinformatics 2012; 28: 729-730
    CrossrefPubMedGoogle Scholar
  • 36 Akalin A, Kormaksson M, Li S. et al. methylKit: A comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome Biol 2012; 13: R87
    CrossrefPubMedGoogle Scholar
  • 37 Starnawska A, Demontis D, McQuillin A. et al. Hypomethylation of FAM63B in bipolar disorder patients. Clin Epigenetics 2016; 8: 52
    CrossrefPubMedGoogle Scholar
  • 38 Middleton FA, Mirnics K, Pierri JN. et al. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 2002; 22: 2718-2729
    CrossrefPubMedGoogle Scholar
  • 39 Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration 1976
    PubMed
  • 40 Spitzer RL, Kroenke K, Williams JB. et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166: 1092-1097
    Google Scholar
  • 41 Szuhany KL, Young A, Mauro C. et al. Impact of sleep on complicated grief severity and outcomes. Depress Anxiety 2020; 37: 73-80
    CrossrefPubMedGoogle Scholar
  • 42 Yeung A, Feldman G, Pedrelli P. et al. The Quick Inventory of Depressive Symptomatology, clinician rated and self-report: A psychometric assessment in Chinese Americans with major depressive disorder. J Nerv Ment Dis 2012; 200: 712-715
    CrossrefPubMedGoogle Scholar
  • 43 Snaith RP, Hamilton M, Morley S. et al. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 1995; 167: 99-103
    CrossrefPubMedGoogle Scholar
  • 44 Greenwood CJ, Youssef GJ, Letcher P. et al. A comparison of penalised regression methods for informing the selection of predictive markers. PLoS One 2020; 15: e0242730
    CrossrefPubMedGoogle Scholar
  • 45 Trivedi MH, Papakostas GI, Jackson WC. et al. Implementing ,easurement-based care to determine and treat inadequate response. J Clin Psychiatry 2020; 81: OT19037BR1
    CrossrefPubMedGoogle Scholar
  • 46 Consortium B. Quantitative comparison of DNA methylation assays for biomarker development and clinical applications. Nat Biotechnol 2016; 34: 726-737
    CrossrefPubMedGoogle Scholar
  • 47 Starnawska A, Demontis D. Role of DNA methylation in mediating genetic risk of psychiatric disorders. Front Psychiatry 2021; 12: 596821
    CrossrefPubMedGoogle Scholar
  • 48 Jenniches I, Ternes S, Albayram O. et al. Anxiety, stress, and fear response in mice with reduced endocannabinoid levels. Biol Psychiatry 2016; 79: 858-868
    CrossrefPubMedGoogle Scholar
  • 49 Schuele LL, Glasmacher S, Gertsch J. et al. Diacylglycerol lipase alpha in astrocytes is involved in maternal care and affective behaviors. Glia 2021; 69: 377-391
    CrossrefPubMedGoogle Scholar
  • 50 Xue SS, Xue F, Ma QR. et al. Repetitive high-frequency transcranial magnetic stimulation reverses depressive-like behaviors and protein expression at hippocampal synapses in chronic unpredictable stress-treated rats by enhancing endocannabinoid signaling. Pharmacol Biochem Behav 2019; 184: 172738
    CrossrefPubMedGoogle Scholar
  • 51 Sheehan DV, Mancini M, Wang J. et al. Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors. Hum Psychopharmacol 2016; 31: 53-63
    CrossrefPubMedGoogle Scholar
  • 52 Voineskos D, Blumberger DM, Rogasch NC. et al. Neurophysiological effects of repetitive transcranial magnetic stimulation (rTMS) in treatment resistant depression. Clin Neurophysiol 2021; 132: 2306-2316
    CrossrefPubMedGoogle Scholar